Media coverage about Mylan (NASDAQ:MYL) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mylan earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.5323411175624 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have effected Accern’s analysis:
A number of equities research analysts recently weighed in on MYL shares. Cantor Fitzgerald set a $41.00 target price on shares of Mylan and gave the stock a “hold” rating in a report on Tuesday, December 26th. Zacks Investment Research lowered shares of Mylan from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. UBS set a $46.00 target price on shares of Mylan and gave the stock a “buy” rating in a report on Monday, December 4th. Susquehanna Bancshares restated a “positive” rating and issued a $55.00 target price (up previously from $47.00) on shares of Mylan in a report on Thursday, January 25th. Finally, Morgan Stanley upgraded shares of Mylan from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $39.00 to $50.00 in a report on Tuesday, March 6th. Nine analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $46.62.
MYL stock traded up $0.75 during trading hours on Wednesday, reaching $41.16. 3,190,810 shares of the company’s stock traded hands, compared to its average volume of 5,543,973. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.73 and a current ratio of 1.13. The stock has a market cap of $21,003.09, a price-to-earnings ratio of 31.91, a price-to-earnings-growth ratio of 1.30 and a beta of 1.35. Mylan has a 52-week low of $29.39 and a 52-week high of $47.82.
Mylan (NASDAQ:MYL) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $1.43 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.41 by $0.02. The firm had revenue of $3.24 billion during the quarter, compared to analyst estimates of $3.29 billion. Mylan had a net margin of 5.84% and a return on equity of 19.14%. The company’s revenue for the quarter was down .9% on a year-over-year basis. During the same quarter last year, the business posted $1.57 EPS. analysts expect that Mylan will post 5.38 earnings per share for the current year.
In other Mylan news, Director Robert J. Coury sold 150,000 shares of the stock in a transaction dated Friday, March 2nd. The shares were sold at an average price of $40.10, for a total value of $6,015,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Anthony Mauro sold 12,257 shares of the firm’s stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $40.35, for a total transaction of $494,569.95. Following the sale, the insider now owns 147,435 shares of the company’s stock, valued at approximately $5,949,002.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 344,287 shares of company stock valued at $14,409,960. Company insiders own 0.69% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/21/mylan-myl-earning-somewhat-positive-media-coverage-report-shows.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.